+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Tumor Drugs Market Research Report by Indications, Route of Administration, Drug , Drug Class, End-user, Distribution Channels, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5367839
  • Report
  • October 2021
  • Region: Global
  • 195 pages
  • 360iResearch™
UP TO OFF
until Jan 01st 2022
Global Anti-Tumor Drugs Market is Projected to Reach USD 49.27 Billion by 2026, Registering a CAGR of 12.05%

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Johnson & Johnson
  • MORE
The Global Anti-Tumor Drugs Market size was estimated at USD 24.89 billion in 2020, is expected to reach USD 27.80 billion in 2021, and projected to grow at a CAGR of 12.05% reaching USD 49.27 billion by 2026.



Market Statistics


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage


This research report categorizes the Anti-Tumor Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Indications, the market was studied across Breast Cancer, Leukemia, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on Route of Administration, the market was studied across Intra-muscular, Intraperitoneal, Intravenous, Intraventricular / Intrathecal, Intravesicular, Oral, Subcutaneous, and Topical.
  • Based on Drug, the market was studied across Alkylating Agents, Antimetabolites, Antitumor Antibiotic., Mitotic Inhibitors, and Topoisomerase Inhibitors.
  • Based on Drug Class, the market was studied across . Hormonal Therapy, Cytotoxics, and Targeted Therapy. The Targeted Therapy is further studied across Monoclonal Antibodies and Small Molecule Inhibitors.
  • Based on End-user, the market was studied across Clinics, Hospitals, and Specialty Centers.
  • Based on Distribution Channels, the market was studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The analyst's ongoing research amplifies their research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Tumor Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Tumor Drugs Market, including Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb, Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Anti-Tumor Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Tumor Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Tumor Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Anti-Tumor Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Anti-Tumor Drugs Market?
6. What is the market share of the leading vendors in the Global Anti-Tumor Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Anti-Tumor Drugs Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Johnson & Johnson
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Rise in incidence of cancer across the globe with the surge in the geriatric population
5.2.2. Growing awareness regarding early diagnosis and treatment for the cancer
5.2.3. Increase in expenditures on healthcare by government
5.3. Restraints
5.3.1. Unfavorable outcomes associated with the use of cancer drugs
5.4. Opportunities
5.4.1. Rise in the number of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
5.4.2. Emerging market growth potential in developing nations such as Asian and African economies
5.5. Challenges
5.5.1. High cost of anti-cancer drugs and low survival rate

6. Anti-Tumor Drugs Market, by Indications
6.1. Introduction
6.2. Breast Cancer
6.3. Leukemia
6.4. Lung Cancer
6.5. Melanoma
6.6. Prostate Cancer

7. Anti-Tumor Drugs Market, by Route of Administration
7.1. Introduction
7.2. Intra-muscular
7.3. Intraperitoneal
7.4. Intravenous
7.5. Intraventricular / Intrathecal
7.6. Intravesicular
7.7. Oral
7.8. Subcutaneous
7.9. Topical

8. Anti-Tumor Drugs Market, by Drug
8.1. Introduction
8.2. Alkylating Agents
8.3. Antimetabolites
8.4. Antitumor Antibiotic.
8.5. Mitotic Inhibitors
8.6. Topoisomerase Inhibitors

9. Anti-Tumor Drugs Market, by Drug Class
9.1. Introduction
9.2. . Hormonal Therapy
9.3. Cytotoxics
9.4. Targeted Therapy
9.4.1. Monoclonal Antibodies
9.4.2. Small Molecule Inhibitors

10. Anti-Tumor Drugs Market, by End-user
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Specialty Centers

11. Anti-Tumor Drugs Market, by Distribution Channels
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Retail Pharmacies

12. Americas Anti-Tumor Drugs Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Anti-Tumor Drugs Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand

14. Europe, Middle East & Africa Anti-Tumor Drugs Market
14.1. Introduction
14.2. France
14.3. Germany
14.4. Italy
14.5. Netherlands
14.6. Qatar
14.7. Russia
14.8. Saudi Arabia
14.9. South Africa
14.10. Spain
14.11. United Arab Emirates
14.12. United Kingdom

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, by Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Amgen Inc.
16.2. Astellas Pharma Inc.
16.3. AstraZeneca plc
16.4. Bayer AG
16.5. Biogen Inc.
16.6. Bristol-Myers Squibb
16.7. Celgene Corporation
16.8. Eisai Co., Ltd.
16.9. Eli Lilly and Company
16.10. F. Hoffmann-La Roche AG
16.11. Johnson & Johnson
16.12. Merck & Co., Inc.
16.13. Novartis International AG
16.14. Otsuka Pharmaceutical Co., Ltd.
16.15. Pfizer Inc.
16.16. Sanofi S.A.
16.17. Takeda Pharmaceutical Company Limited
16.18. Teva Pharmaceutical Industries Ltd.

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures
Figure 1. Global Anti-Tumor Drugs Market Size, 2020 vs 2026 (USD Billion)
Figure 2. Global Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 3. Global Anti-Tumor Drugs Market: Market Dynamics
Figure 4. Global Anti-Tumor Drugs Market Size, by Indications, 2020 vs 2026 (%)
Figure 5. Global Anti-Tumor Drugs Market Size, by Indications, 2020 vs 2026 (USD Billion)
Figure 6. Competitive Strategic Window for Global Anti-Tumor Drugs Market Size, by Indications, 2026
Figure 7. Global Anti-Tumor Drugs Market Size, by Breast Cancer, 2018-2026 (USD Billion)
Figure 8. Global Anti-Tumor Drugs Market Size, by Breast Cancer, by Region, 2020 vs 2026 (USD Billion)
Figure 9. Global Anti-Tumor Drugs Market Size, by Leukemia, 2018-2026 (USD Billion)
Figure 10. Global Anti-Tumor Drugs Market Size, by Leukemia, by Region, 2020 vs 2026 (USD Billion)
Figure 11. Global Anti-Tumor Drugs Market Size, by Lung Cancer, 2018-2026 (USD Billion)
Figure 12. Global Anti-Tumor Drugs Market Size, by Lung Cancer, by Region, 2020 vs 2026 (USD Billion)
Figure 13. Global Anti-Tumor Drugs Market Size, by Melanoma, 2018-2026 (USD Billion)
Figure 14. Global Anti-Tumor Drugs Market Size, by Melanoma, by Region, 2020 vs 2026 (USD Billion)
Figure 15. Global Anti-Tumor Drugs Market Size, by Prostate Cancer, 2018-2026 (USD Billion)
Figure 16. Global Anti-Tumor Drugs Market Size, by Prostate Cancer, by Region, 2020 vs 2026 (USD Billion)
Figure 17. Global Anti-Tumor Drugs Market Size, by Route of Administration, 2020 vs 2026 (%)
Figure 18. Global Anti-Tumor Drugs Market Size, by Route of Administration, 2020 vs 2026 (USD Billion)
Figure 19. Competitive Strategic Window for Global Anti-Tumor Drugs Market Size, by Route of Administration, 2026
Figure 20. Global Anti-Tumor Drugs Market Size, by Intra-Muscular, 2018-2026 (USD Billion)
Figure 21. Global Anti-Tumor Drugs Market Size, by Intra-Muscular, by Region, 2020 vs 2026 (USD Billion)
Figure 22. Global Anti-Tumor Drugs Market Size, by Intraperitoneal, 2018-2026 (USD Billion)
Figure 23. Global Anti-Tumor Drugs Market Size, by Intraperitoneal, by Region, 2020 vs 2026 (USD Billion)
Figure 24. Global Anti-Tumor Drugs Market Size, by Intravenous, 2018-2026 (USD Billion)
Figure 25. Global Anti-Tumor Drugs Market Size, by Intravenous, by Region, 2020 vs 2026 (USD Billion)
Figure 26. Global Anti-Tumor Drugs Market Size, by Intraventricular / Intrathecal, 2018-2026 (USD Billion)
Figure 27. Global Anti-Tumor Drugs Market Size, by Intraventricular / Intrathecal, by Region, 2020 vs 2026 (USD Billion)
Figure 28. Global Anti-Tumor Drugs Market Size, by Intravesicular, 2018-2026 (USD Billion)
Figure 29. Global Anti-Tumor Drugs Market Size, by Intravesicular, by Region, 2020 vs 2026 (USD Billion)
Figure 30. Global Anti-Tumor Drugs Market Size, by Oral, 2018-2026 (USD Billion)
Figure 31. Global Anti-Tumor Drugs Market Size, by Oral, by Region, 2020 vs 2026 (USD Billion)
Figure 32. Global Anti-Tumor Drugs Market Size, by Subcutaneous, 2018-2026 (USD Billion)
Figure 33. Global Anti-Tumor Drugs Market Size, by Subcutaneous, by Region, 2020 vs 2026 (USD Billion)
Figure 34. Global Anti-Tumor Drugs Market Size, by Topical, 2018-2026 (USD Billion)
Figure 35. Global Anti-Tumor Drugs Market Size, by Topical, by Region, 2020 vs 2026 (USD Billion)
Figure 36. Global Anti-Tumor Drugs Market Size, by Drug, 2020 vs 2026 (%)
Figure 37. Global Anti-Tumor Drugs Market Size, by Drug, 2020 vs 2026 (USD Billion)
Figure 38. Competitive Strategic Window for Global Anti-Tumor Drugs Market Size, by Drug, 2026
Figure 39. Global Anti-Tumor Drugs Market Size, by Alkylating Agents, 2018-2026 (USD Billion)
Figure 40. Global Anti-Tumor Drugs Market Size, by Alkylating Agents, by Region, 2020 vs 2026 (USD Billion)
Figure 41. Global Anti-Tumor Drugs Market Size, by Antimetabolites, 2018-2026 (USD Billion)
Figure 42. Global Anti-Tumor Drugs Market Size, by Antimetabolites, by Region, 2020 vs 2026 (USD Billion)
Figure 43. Global Anti-Tumor Drugs Market Size, by Antitumor Antibiotic. 2018-2026 (USD Billion)
Figure 44. Global Anti-Tumor Drugs Market Size, by Antitumor Antibiotic. by Region, 2020 vs 2026 (USD Billion)
Figure 45. Global Anti-Tumor Drugs Market Size, by Mitotic Inhibitors, 2018-2026 (USD Billion)
Figure 46. Global Anti-Tumor Drugs Market Size, by Mitotic Inhibitors, by Region, 2020 vs 2026 (USD Billion)
Figure 47. Global Anti-Tumor Drugs Market Size, by Topoisomerase Inhibitors, 2018-2026 (USD Billion)
Figure 48. Global Anti-Tumor Drugs Market Size, by Topoisomerase Inhibitors, by Region, 2020 vs 2026 (USD Billion)
Figure 49. Global Anti-Tumor Drugs Market Size, by Drug Class, 2020 vs 2026 (%)
Figure 50. Global Anti-Tumor Drugs Market Size, by Drug Class, 2020 vs 2026 (USD Billion)
Figure 51. Competitive Strategic Window for Global Anti-Tumor Drugs Market Size, by Drug Class, 2026
Figure 52. Global Anti-Tumor Drugs Market Size, by . Hormonal Therapy, 2018-2026 (USD Billion)
Figure 53. Global Anti-Tumor Drugs Market Size, by . Hormonal Therapy, by Region, 2020 vs 2026 (USD Billion)
Figure 54. Global Anti-Tumor Drugs Market Size, by Cytotoxics, 2018-2026 (USD Billion)
Figure 55. Global Anti-Tumor Drugs Market Size, by Cytotoxics, by Region, 2020 vs 2026 (USD Billion)
Figure 56. Global Anti-Tumor Drugs Market Size, by Targeted Therapy, 2018-2026 (USD Billion)
Figure 57. Global Anti-Tumor Drugs Market Size, by Targeted Therapy, by Region, 2020 vs 2026 (USD Billion)
Figure 58. Global Anti-Tumor Drugs Market Size, by Monoclonal Antibodies, 2018-2026 (USD Billion)
Figure 59. Global Anti-Tumor Drugs Market Size, by Monoclonal Antibodies, by Region, 2020 vs 2026 (USD Billion)
Figure 60. Global Anti-Tumor Drugs Market Size, by Small Molecule Inhibitors, 2018-2026 (USD Billion)
Figure 61. Global Anti-Tumor Drugs Market Size, by Small Molecule Inhibitors, by Region, 2020 vs 2026 (USD Billion)
Figure 62. Global Anti-Tumor Drugs Market Size, by End-user, 2020 vs 2026 (%)
Figure 63. Global Anti-Tumor Drugs Market Size, by End-user, 2020 vs 2026 (USD Billion)
Figure 64. Competitive Strategic Window for Global Anti-Tumor Drugs Market Size, by End-user, 2026
Figure 65. Global Anti-Tumor Drugs Market Size, by Clinics, 2018-2026 (USD Billion)
Figure 66. Global Anti-Tumor Drugs Market Size, by Clinics, by Region, 2020 vs 2026 (USD Billion)
Figure 67. Global Anti-Tumor Drugs Market Size, by Hospitals, 2018-2026 (USD Billion)
Figure 68. Global Anti-Tumor Drugs Market Size, by Hospitals, by Region, 2020 vs 2026 (USD Billion)
Figure 69. Global Anti-Tumor Drugs Market Size, by Specialty Centers, 2018-2026 (USD Billion)
Figure 70. Global Anti-Tumor Drugs Market Size, by Specialty Centers, by Region, 2020 vs 2026 (USD Billion)
Figure 71. Global Anti-Tumor Drugs Market Size, by Distribution Channels, 2020 vs 2026 (%)
Figure 72. Global Anti-Tumor Drugs Market Size, by Distribution Channels, 2020 vs 2026 (USD Billion)
Figure 73. Competitive Strategic Window for Global Anti-Tumor Drugs Market Size, by Distribution Channels, 2026
Figure 74. Global Anti-Tumor Drugs Market Size, by Hospital Pharmacies, 2018-2026 (USD Billion)
Figure 75. Global Anti-Tumor Drugs Market Size, by Hospital Pharmacies, by Region, 2020 vs 2026 (USD Billion)
Figure 76. Global Anti-Tumor Drugs Market Size, by Retail Pharmacies, 2018-2026 (USD Billion)
Figure 77. Global Anti-Tumor Drugs Market Size, by Retail Pharmacies, by Region, 2020 vs 2026 (USD Billion)
Figure 78. Americas Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 79. Argentina Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 80. Brazil Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 81. Canada Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 82. Mexico Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 83. United States Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 84. Asia-Pacific Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 85. Australia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 86. China Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 87. India Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 88. Indonesia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 89. Japan Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 90. Malaysia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 91. Philippines Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 92. Singapore Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 93. South Korea Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 94. Taiwan Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 95. Thailand Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 96. Europe, Middle East & Africa Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 97. France Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 98. Germany Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 99. Italy Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 100. Netherlands Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 101. Qatar Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 102. Russia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 103. Saudi Arabia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 104. South Africa Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 105. Spain Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 106. United Arab Emirates Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 107. United Kingdom Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Figure 108. Global Anti-Tumor Drugs Market: FPNV Positioning Matrix
Figure 109. Global Anti-Tumor Drugs Market: Share, by Key Player, 2020
Figure 110. Competitive Scenario Analysis in Global Anti-Tumor Drugs Market, by Type

List of Tables
Table 1. Global Anti-Tumor Drugs Market: Market Segmentation & Coverage
Table 2. United States Dollar Exchange Rate, 2016–2020
Table 3. Global Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 4. Global Anti-Tumor Drugs Market Size, by Indications, 2018-2026 (USD Billion)
Table 5. Global Anti-Tumor Drugs Market Size, by Breast Cancer, by Region, 2018-2026 (USD Billion)
Table 6. Global Anti-Tumor Drugs Market Size, by Leukemia, by Region, 2018-2026 (USD Billion)
Table 7. Global Anti-Tumor Drugs Market Size, by Lung Cancer, by Region, 2018-2026 (USD Billion)
Table 8. Global Anti-Tumor Drugs Market Size, by Melanoma, by Region, 2018-2026 (USD Billion)
Table 9. Global Anti-Tumor Drugs Market Size, by Prostate Cancer, by Region, 2018-2026 (USD Billion)
Table 10. Global Anti-Tumor Drugs Market Size, by Route of Administration, 2018-2026 (USD Billion)
Table 11. Global Anti-Tumor Drugs Market Size, by Intra-Muscular, by Region, 2018-2026 (USD Billion)
Table 12. Global Anti-Tumor Drugs Market Size, by Intraperitoneal, by Region, 2018-2026 (USD Billion)
Table 13. Global Anti-Tumor Drugs Market Size, by Intravenous, by Region, 2018-2026 (USD Billion)
Table 14. Global Anti-Tumor Drugs Market Size, by Intraventricular / Intrathecal, by Region, 2018-2026 (USD Billion)
Table 15. Global Anti-Tumor Drugs Market Size, by Intravesicular, by Region, 2018-2026 (USD Billion)
Table 16. Global Anti-Tumor Drugs Market Size, by Oral, by Region, 2018-2026 (USD Billion)
Table 17. Global Anti-Tumor Drugs Market Size, by Subcutaneous, by Region, 2018-2026 (USD Billion)
Table 18. Global Anti-Tumor Drugs Market Size, by Topical, by Region, 2018-2026 (USD Billion)
Table 19. Global Anti-Tumor Drugs Market Size, by Drug, 2018-2026 (USD Billion)
Table 20. Global Anti-Tumor Drugs Market Size, by Alkylating Agents, by Region, 2018-2026 (USD Billion)
Table 21. Global Anti-Tumor Drugs Market Size, by Antimetabolites, by Region, 2018-2026 (USD Billion)
Table 22. Global Anti-Tumor Drugs Market Size, by Antitumor Antibiotic. by Region, 2018-2026 (USD Billion)
Table 23. Global Anti-Tumor Drugs Market Size, by Mitotic Inhibitors, by Region, 2018-2026 (USD Billion)
Table 24. Global Anti-Tumor Drugs Market Size, by Topoisomerase Inhibitors, by Region, 2018-2026 (USD Billion)
Table 25. Global Anti-Tumor Drugs Market Size, by Drug Class, 2018-2026 (USD Billion)
Table 26. Global Anti-Tumor Drugs Market Size, by . Hormonal Therapy, by Region, 2018-2026 (USD Billion)
Table 27. Global Anti-Tumor Drugs Market Size, by Cytotoxics, by Region, 2018-2026 (USD Billion)
Table 28. Global Anti-Tumor Drugs Market Size, by Targeted Therapy, by Region, 2018-2026 (USD Billion)
Table 29. Global Anti-Tumor Drugs Market Size, by Monoclonal Antibodies, by Region, 2018-2026 (USD Billion)
Table 30. Global Anti-Tumor Drugs Market Size, by Small Molecule Inhibitors, by Region, 2018-2026 (USD Billion)
Table 31. Global Anti-Tumor Drugs Market Size, by End-user, 2018-2026 (USD Billion)
Table 32. Global Anti-Tumor Drugs Market Size, by Clinics, by Region, 2018-2026 (USD Billion)
Table 33. Global Anti-Tumor Drugs Market Size, by Hospitals, by Region, 2018-2026 (USD Billion)
Table 34. Global Anti-Tumor Drugs Market Size, by Specialty Centers, by Region, 2018-2026 (USD Billion)
Table 35. Global Anti-Tumor Drugs Market Size, by Distribution Channels, 2018-2026 (USD Billion)
Table 36. Global Anti-Tumor Drugs Market Size, by Hospital Pharmacies, by Region, 2018-2026 (USD Billion)
Table 37. Global Anti-Tumor Drugs Market Size, by Retail Pharmacies, by Region, 2018-2026 (USD Billion)
Table 38. Americas Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 39. Argentina Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 40. Brazil Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 41. Canada Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 42. Mexico Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 43. United States Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 44. Asia-Pacific Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 45. Australia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 46. China Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 47. India Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 48. Indonesia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 49. Japan Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 50. Malaysia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 51. Philippines Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 52. Singapore Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 53. South Korea Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 54. Taiwan Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 55. Thailand Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 56. Europe, Middle East & Africa Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 57. France Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 58. Germany Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 59. Italy Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 60. Netherlands Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 61. Qatar Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 62. Russia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 63. Saudi Arabia Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 64. South Africa Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 65. Spain Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 66. United Arab Emirates Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 67. United Kingdom Anti-Tumor Drugs Market Size, 2018-2026 (USD Billion)
Table 68. Global Anti-Tumor Drugs Market: Scores
Table 69. Global Anti-Tumor Drugs Market: Business Strategy
Table 70. Global Anti-Tumor Drugs Market: Product Satisfaction
Table 71. Global Anti-Tumor Drugs Market: Ranking
Table 72. Global Anti-Tumor Drugs Market: Share, by Key Player, 2020
Table 73. Global Anti-Tumor Drugs Market: Merger & Acquisition
Table 74. Global Anti-Tumor Drugs Market: Agreement, Collaboration & Partnership
Table 75. Global Anti-Tumor Drugs Market: New Product Launch & Enhancement
Table 76. Global Anti-Tumor Drugs Market: Investment & Funding
Table 77. Global Anti-Tumor Drugs Market: Award, Recognition & Expansion
Table 78. Global Anti-Tumor Drugs Market: License & Pricing
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll